2021
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy
Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer 2021, 22: 587-595. PMID: 34544620, DOI: 10.1016/j.cllc.2021.08.008.Peer-Reviewed Original ResearchConceptsMolecular risk stratificationAdjuvant chemotherapyDisease-free survivalEGFR mutation statusAdjuvant interventionRisk stratificationEGFR patientsNSCLC patientsEGFR statusMutation statusSmall cell lung cancer patientsNon-squamous NSCLC patientsCell lung cancer patientsStage IA NSCLCStage IB patientsThird-generation TKIsEarly-stage NSCLCNon-Squamous NonLung cancer patientsEarly-stage cohortIB patientsProspective studyResidual diseaseCancer patientsEGFR mutations
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance indexCase report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass
Woodard GA, Lee H, Fels Elliott DR, Jones KD, Wong J, Jablons DM, Ihnken K. Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass. Journal Of Cardiothoracic Surgery 2019, 14: 158. PMID: 31488186, PMCID: PMC6728940, DOI: 10.1186/s13019-019-0980-1.Peer-Reviewed Original ResearchConceptsLeft internal mammary arteryDissection bedEstrogen receptorBreast cancerChest radiationHormonal therapyBypass surgeryRecurrent cancerNon-ST elevation myocardial infarctionCoronary artery bypass surgeryRecurrent metastatic breast cancerThree-vessel coronary artery bypassTumor cellsBreast intraductal carcinomaPrior chest radiationCoronary artery bypassArtery bypass surgeryInternal mammary arteryRecurrent breast cancerSaphenous vein graftsElevation myocardial infarctionMetastatic breast cancerHistory of cancerAreas of necrosisDense fibrous tissueIncorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging
Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging. Journal Of Thoracic Oncology 2019, 14: 1223-1232. PMID: 30959120, DOI: 10.1016/j.jtho.2019.03.015.Peer-Reviewed Original Research
2018
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation
Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer 2018, 20: e137-e141. PMID: 30553716, DOI: 10.1016/j.cllc.2018.11.003.Peer-Reviewed Original Research
2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.Peer-Reviewed Original ResearchConceptsHigh-risk patientsDisease-free survivalLow-risk patientsAdjuvant chemotherapyNational Comprehensive Cancer Network guidelinesCell lung cancer patientsMolecular profilingEarly-stage NSCLCHigh-risk criteriaLog-rank analysisCell lung cancerHigh-risk designationLung cancer patientsKaplan-Meyer estimatesAdjuvant treatmentNonsquamous NSCLCOccult metastasesStage IAStage NSCLCAdjuvant interventionClinicopathologic characteristicsComplete resectionConsecutive patientsDisease recurrenceNCCN criteria
2016
Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity
Woodard GA, Crockard JC, Clary‐Macy C, Zoon‐Besselink C, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity. Journal Of Surgical Oncology 2016, 114: 838-847. PMID: 27569043, DOI: 10.1002/jso.24409.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinomaChemoradiotherapy, AdjuvantEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesHumansLaparoscopyMaleMiddle AgedMinimally Invasive Surgical ProceduresNeoadjuvant TherapyNeoplasm Recurrence, LocalNeuroendocrine TumorsPostoperative ComplicationsProspective StudiesSurvival AnalysisThoracotomyTreatment OutcomeConceptsNeoadjuvant chemoradiationEsophagectomy approachesLong-term overall survival rateInvasive Ivor Lewis esophagectomyLow perioperative morbidityPostoperative complication rateClear survival benefitFive-year survivalIvor Lewis esophagectomyMajority of patientsOverall survival rateEsophageal cancer patientsInvasive esophagectomy (MIE) approachPatients 58Hospital stayNeoadjuvant treatmentPerioperative complicationsPerioperative morbidityPostoperative complicationsProspective databaseClinical characteristicsOverall survivalSurvival benefitComplication rateMajor complicationsGli promotes epithelial-mesenchymal transition in human lung adenocarcinomas
Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget 2016, 5: 80415-80425. PMID: 27533453, PMCID: PMC5348330, DOI: 10.18632/oncotarget.11246.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAdenocarcinomaAdenocarcinoma of LungAnimalsAntigens, CDAntineoplastic AgentsCadherinsCell MovementEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHedgehog ProteinsHumansLung NeoplasmsMaleMice, NudeMiddle AgedNeoplasm InvasivenessSignal TransductionSmoothened ReceptorTime FactorsTumor BurdenXenograft Model Antitumor AssaysZinc Finger Protein GLI1ConceptsEpithelial-mesenchymal transitionLung adenocarcinomaE-cadherin expressionTumor growthLung adenocarcinoma metastasisPotential therapeutic targetInhibition of GLICell migrationAdenocarcinoma metastasisLung cancerInvasion/metastasisTumor invasion/metastasisIndependent cohortGLI inhibitorsSmall molecule inhibitorsTherapeutic targetAdenocarcinomaHuman lungTherapeutic agentsMetastasisCell invasionWound healingCommon typeRole of GliMolecule inhibitorsConsensus Report of the 2015 Weinman International Conference on Mesothelioma
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal Of Thoracic Oncology 2016, 11: 1246-1262. PMID: 27453164, PMCID: PMC5551435, DOI: 10.1016/j.jtho.2016.04.028.Peer-Reviewed Original ResearchConceptsMalignant mesotheliomaOverall survivalHigh mobility group box 1Mobility group box 1Development of MMIncidence of MMGroup box 1Novel therapeutic approachesNational Cancer InstitutePublic health authoritiesU.S. National Cancer InstitutePreventable malignancyStandard chemotherapyCancer CenterBlood biomarkersLung cancerMineral fibersClinical trialsCurrent treatmentOccupational exposureProtein 1 mutationConsensus reportTherapeutic approachesGermline BRCA1Clinical OncologySignificance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics
Yang D, Woodard G, Zhou C, Wang X, Liu Z, Ye Z, Li K. Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics. Thoracic Cancer 2016, 7: 535-542. PMID: 27766777, PMCID: PMC5130210, DOI: 10.1111/1759-7714.12363.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse Evaluation CriteriaTumor cavitationPrognostic informationTreatment responseTumor responseTumor densitySignificant differencesPrediction of PFSRadiographic treatment responseAdditional prognostic informationUseful prognostic signCertain radiographic signsPrognostic signTumor diameterLung cancerShort-axis sizeRadiographic signsTumor assessmentPatientsSolid tumorsTumor changesRECIST1.1Imaging characteristicsPFSWhole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas
Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget 2016, 7: 8321-8331. PMID: 26824986, PMCID: PMC4884995, DOI: 10.18632/oncotarget.7032.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternExomeFemaleGenome, HumanHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansImmunoenzyme TechniquesLoss of HeterozygosityLung NeoplasmsMesotheliomaMesothelioma, MalignantMiddle AgedMutationPleural NeoplasmsPrognosisProtein MethyltransferasesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsMalignant pleural mesotheliomaPrimary cancerPleural mesotheliomaGenetic mechanismsDeep sequencingAdditional primary cancersMultiple primary cancersPrimary lung cancerPrimary cancer developmentAllelic lossNew genetic mechanismWhole-exome sequencingDistinct genomic alterationsMPM patientsRare malignancyPerineural invasionPoor prognosisTherapeutic optionsLung cancerLoss of heterozygosityTP53 mutationsCancer developmentPatientsExome sequencingCancer
2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCell MovementChemotherapy, AdjuvantCombined Modality TherapyCyclophosphamideDeoxycytidineDown-RegulationDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGemcitabineGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLungLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingOrganoplatinum CompoundsPaclitaxelPneumonectomyPrognosisRNA InterferenceRNA, Small InterferingTranscription FactorsVinblastineVinorelbineConceptsLung squamous cell carcinomaSquamous cell carcinomaLung SCC patientsNon-small cell lung cancerLung SCC cellsLung SCC cell linesSCC patientsSCC cell linesAdjuvant chemotherapyCell carcinomaPredictive markerSCC cellsEMX2 expressionImproved overall survivalCurrent staging methodsTissue samplesCell lung cancerNovel prognostic markerAdjacent normal tissuesCell linesOverall survivalSurgical resectionLung cancerPatient outcomesPrognostic marker
2014
Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes
2012
Normal Alcohol Metabolism after Gastric Banding and Sleeve Gastrectomy: A Case-Cross-Over Trial
Changchien EM, Woodard GA, Hernandez-Boussard T, Morton JM. Normal Alcohol Metabolism after Gastric Banding and Sleeve Gastrectomy: A Case-Cross-Over Trial. Journal Of The American College Of Surgeons 2012, 215: 475-479. PMID: 22770864, DOI: 10.1016/j.jamcollsurg.2012.06.008.Peer-Reviewed Original ResearchConceptsLaparoscopic adjustable gastric bandingLaparoscopic sleeve gastrectomyGastric bypass patientsGastric bandingAlcohol metabolismSleeve gastrectomyBypass patientsPostoperative gastric bypass patientsExcess weight lossAdjustable gastric bandingBariatric surgery patientsViable treatment optionPublic health concernGastric bypassBariatric proceduresBariatric surgeryPreoperative levelsSevere obesitySurgery patientsTreatment optionsPeak BACPatientsDrinking habitsTotal participantsGastrectomyLaparoscopic vs Open Gastric Bypass Surgery: Differences in Patient Demographics, Safety, and Outcomes
Banka G, Woodard G, Hernandez-Boussard T, Morton JM. Laparoscopic vs Open Gastric Bypass Surgery: Differences in Patient Demographics, Safety, and Outcomes. JAMA Surgery 2012, 147: 550-556. PMID: 22786543, DOI: 10.1001/archsurg.2012.195.Peer-Reviewed Original ResearchConceptsLRYGB patientsGastric bypassMore complicationsOpen gastric bypass surgeryQuality Patient Safety IndicatorsRetrospective cohort studyGastric bypass surgeryHigh-volume hospitalsLonger median lengthNationwide Inpatient SamplePopulation-based studyLength of stayPatient safety indicatorsLower odds ratioHigher total chargesNumber of proceduresLRYGB cohortsNonroutine dispositionLaparoscopic RouxOpen RouxBypass surgeryPatient demographicsCohort studyComorbidity differencesMedian length
2011
Halo Effect for Bariatric Surgery: Collateral Weight Loss in Patients' Family Members
Woodard GA, Encarnacion B, Peraza J, Hernandez-Boussard T, Morton J. Halo Effect for Bariatric Surgery: Collateral Weight Loss in Patients' Family Members. JAMA Surgery 2011, 146: 1185-1190. PMID: 22006878, DOI: 10.1001/archsurg.2011.244.Peer-Reviewed Original ResearchConceptsGastric bypass surgeryBypass surgeryBody mass indexPatients' family membersAdult family membersHealthy behaviorsBariatric surgeryMass indexWeight lossLower body mass indexFamily membersMultidimensional health assessmentActivity levelsChildren of patientsSignificant weight lossDaily activity levelsQuality of lifeBariatric centerLifestyle counselingMorbid obesitySecondary outcomesWaist circumferenceObese childrenEffective treatmentUncontrollable eating
2010
Impaired Alcohol Metabolism after Gastric Bypass Surgery: A Case-Crossover Trial
Woodard GA, Downey J, Hernandez-Boussard T, Morton JM. Impaired Alcohol Metabolism after Gastric Bypass Surgery: A Case-Crossover Trial. Journal Of The American College Of Surgeons 2010, 212: 209-214. PMID: 21183366, DOI: 10.1016/j.jamcollsurg.2010.09.020.Peer-Reviewed Original ResearchConceptsGastric bypass surgeryBypass surgeryAlcohol metabolismBreath alcohol contentCase-crossover trialsGastric bypass patientsCase-crossover designEnduring treatmentRYGB patientsGastric bypassBariatric surgeryBypass patientsPreoperative levelsPublic health crisisSevere obesityPostoperative patientsPatientsDouble visionSurgeryDrinking habitsLess alcoholMonthsHealth crisisPoor psychological adjustmentIndustrialized worldCardiac Arrest During Laparoscopic Roux-en-Y Gastric Bypass in a Bariatric Patient with Drug-Associated Long QT Syndrome
Woodard G, Brodsky JB, Morton JM. Cardiac Arrest During Laparoscopic Roux-en-Y Gastric Bypass in a Bariatric Patient with Drug-Associated Long QT Syndrome. Obesity Surgery 2010, 21: 134-137. PMID: 20383601, DOI: 10.1007/s11695-010-0137-8.Peer-Reviewed Original ResearchConceptsLong QT syndromeLaparoscopic RouxObese patientsCardiac arrestQT syndromeIntraoperative cardiac arrestBariatric surgery patientsGastric bypass surgeryProlonged QTc intervalY Gastric BypassGastric bypassBariatric patientsBariatric surgeryBypass surgeryElectrolyte disturbancesObese womenSurgery patientsMedication useQTc intervalCase reportCardiac stressorsTreatment strategiesPatientsCardiac physiologyRouxOne Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding
Woodard GA, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton JM. One Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding. Obesity Surgery 2010, 20: 578-582. PMID: 20186576, DOI: 10.1007/s11695-010-0088-0.Peer-Reviewed Original ResearchConceptsBiochemical cardiovascular risk factorsLaparoscopic adjustable gastric bandingAdjustable gastric bandingCardiovascular risk factorsTotal cholesterolRisk factorsGastric bandingGastric bypassHs-CRPLipoprotein cholesterolExcess weightHigh-sensitivity C-reactive proteinLow-density lipoprotein cholesterolSensitivity C-reactive proteinHigh-density lipoprotein cholesterolBackgroundCoronary artery diseaseConsecutive bariatric patientsPreventable risk factorsY Gastric BypassC-reactive proteinSingle academic institutionCause of deathSignificant weight lossPost-op valuesSignificant improvement
2009
Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial
Woodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T, Morton JM. Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial. Journal Of Gastrointestinal Surgery 2009, 13: 1198-1204. PMID: 19381735, DOI: 10.1007/s11605-009-0891-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultBody Mass IndexConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGastric BypassHumansMaleMiddle AgedObesity, MorbidPatient SatisfactionPostoperative CarePostoperative ComplicationsProbabilityProbioticsProspective StudiesReference ValuesRisk AssessmentTreatment OutcomeWeight LossConceptsGastric bypass surgeryBacterial overgrowthProbiotic groupControl groupWeight lossBypass surgeryGreater percent excess weight lossPercent excess weight lossY Gastric Bypass SurgeryExcess weight lossProspective randomized trialsVitamin B12 levelsMethodsForty-four patientsQuality of lifeEnduring treatmentGastric bypassMorbid obesityB12 levelsPostoperative changesResultsAt 6Randomized trialsVitamin B12 availabilityProbiotic administrationGastrointestinal floraGI microbiota